Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 3/2024

28.01.2024 | Original Article

Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma

verfasst von: Feng-die Huang, Yan-ping Zhong, Guang-yu Sun, Qi-jiang Xu, Zhi-yong Xing, Ke-heng Chen, Lu-sheng Liao, Ming-you Dong

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Liver hepatocellular carcinoma (LIHC) is a serious liver disease worldwide, and its pathogenesis is complicated.

Aims

This study investigated the potential role of FANCA in the advancement and prognosis of LIHC.

Methods

Public databases, quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot (WB) and immunohistochemistry (IHC) were employed to measure FANCA expression between tumor and normal samples. The relationship between FANCA expression and prognosis of LIHC patients were examined. Functional enrichment of FANCA-related genes was performed. Furthermore, univariate and multivariate analyses were conducted to determine the independent prognosis value of FANCA in LIHC. Finally, influence of FANCA knockout on the proliferation, migration, and invasion of HepG2 cell was validated with cloning formation, CCK8, and Transwell assays.

Results

Expression analysis presented that FANCA had high expression level in LIHC tissues and cells. Receiver operating characteristic (ROC) curve analysis showed that FANCA was of great diagnosis value in LIHC. Clinicopathological analysis revealed that FANCA was significantly greater expressed in the advanced stage than in the early stage of LIHC. Univariate, multivariate, and Kaplan–Meier survival analysis confirmed that high expression of FANCA was strongly associated with poor survival of LIHC patients. In addition, high level of FANCA in LIHC showed a negative association with immunoinfiltrated B cells, T cells, and stromal scores. Moreover, Knockout of FANCA significantly inhibited HepG2 cell proliferative activity, migration, and invasion ability.

Conclusions

Our data revealed that high level of FANCA was closely associated with LIHC malignant progression, suggesting its potential utility as a diagnostic, predictive indicator, and therapeutic target.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 2016;67:103–117.CrossRefPubMed
2.
Rumgay H, Arnold M, Ferlay J et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022;6:1598–1606.CrossRef
3.
Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;1:358–380.CrossRef
4.
Li L, Chen J, Xu W, Ding X, Wang X, Liang J. Clinical characteristics of hepatocellular carcinoma patients with normal serum alpha-fetoprotein level: a study of 112 consecutive cases. Asia Pac J Clin Oncol 2018;5:e336–e340.
5.
Turshudzhyan A, Wu GY. Persistently rising alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: a review. J Clin Transl Hepatol 2022;1:159–163.CrossRef
6.
Del VJ, Rofes P, Moreno-Cabrera JM et al. Exploring the role of mutations in Fanconi anemia genes in hereditary cancer patients. Cancers (Basel). 2020;12:829.CrossRef
7.
8.
Morgan NV, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group a gene. Am J Hum Genet 1999;5:1330–1341.CrossRef
9.
Garcia-Higuera I, Taniguchi T, Ganesan S et al. Interaction of the Fanconi anemia proteins and Brca1 in a common pathway. Mol Cell 2001;2:249–262.CrossRef
10.
Pan Y, Yang X, Zhang F et al. A heterozygous hypomorphic mutation of FANCA causes impaired follicle development and subfertility in female mice. Mol Genet Genomics 2021;1:103–112.CrossRef
11.
Peake JD, Noguchi E. Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair. Hum Genet 2022;12:1811–1836.CrossRef
12.
Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer 2018;3:168–185.CrossRef
13.
Rafnar T, Gudbjartsson DF, Sulem P et al. Mutations in Brip1 confer high risk of ovarian cancer. Nat Genet 2011;11:1104–1117.CrossRef
14.
Szklarczyk D, Kirsch R, Koutrouli M et al. The STRING Database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 2023;D1:D638–D646.CrossRef
15.
Li Y, Liu X, Chen H et al. Bioinformatics analysis for the role of Calr in human cancers. PLoS ONE 2021;12:e261254.
16.
Okada M, Shi YB. Cell Proliferation analysis during Xenopus metamorphosis: using 5-ethynyl-2-deoxyuridine (Edu) to stain proliferating intestinal cells. Cold Spring Harb Protoc 2017;9:t97717.
17.
Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: potential for the development of new therapeutics. Cells-Basel 2020;9:1313.CrossRef
18.
Dufour C, Pierri F. Modern management of Fanconi anemia. Hematol Am Soc Hematol Educ Program 2022;1:649–657.CrossRef
19.
Savage SA, Dufour C. Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia. Semin Hematol 2017;2:105–114.CrossRef
20.
Moreno OM, Paredes AC, Suarez-Obando F, Rojas A. An update on Fanconi anemia: clinical, cytogenetic and molecular approaches (review). Biomed Rep 2021;3:74.CrossRef
21.
Altintas B, Giri N, McReynolds LJ, Best A, Alter BP. Genotype–phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort. Haematologica 2023;1:69–82.
22.
Danovi S. Fanconi anemia-associated signature in cancer. Nat Genet 2023;1:1.CrossRef
23.
Chan KK, Abdul-Sater Z, Sheth A et al. Sik2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cells. Mol Oncol 2022;4:860–884.CrossRef
24.
Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol 2021;11:610303.CrossRefPubMedPubMedCentral
25.
Li J, Li X, Zhang C, Zhang C, Wang H. A signature of tumor immune microenvironment genes associated with the prognosis of non-small cell lung cancer. Oncol Rep 2020;3:795–806.
26.
Sun J, Zhang Z, Bao S et al. Identification of tumor immune infiltration-associated LNCRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer 2020;8:e000110.CrossRefPubMedPubMedCentral
27.
Milletti G, Strocchio L, Pagliara D et al. Canonical and noncanonical roles of Fanconi anemia proteins: implications in cancer predisposition. Cancers (Basel) 2020;12:2684.CrossRefPubMed
28.
Ge PL, Li SF, Wang WW et al. Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma. Aging (Albany NY) 2020;6:5479–5499.CrossRef
29.
30.
Xing Z, Chu C, Chen L, Kong X. The use of gene ontology terms and KEGG pathways for analysis and prediction of oncogenes. Biochim Biophys Acta 2016;11:2725–2734.CrossRef
31.
Li H, Lu S, Chen Y et al. Akt2 phosphorylation of Hexokinase 2 at T473 promotes tumorigenesis and metastasis in colon cancer cells via Nf-Kappab, Hif1Alpha, Mmp2, and Mmp9 upregulation. Cell Signal 2019;58:99–110.CrossRefPubMed
32.
Zhao Y, Hu F, Wang Q. Cortactin contributes to the tumorigenesis of gastric cancer by activating Erk/Mmp pathway. Heliyon 2023;7:e18289.CrossRef
33.
Cao ZQ, Wang Z, Leng P. Aberrant N-cadherin expression in cancer. Biomed Pharmacother 2019;118:109320.CrossRefPubMed
34.
Liao S, Yu C, Liu H, Zhang C, Li Y, Zhong X. Long non-coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E-cadherin, N-cadherin, and vimentin. Onco Targets Ther. 2019;12:4099–4107.CrossRefPubMedPubMedCentral
35.
Song Y, Ye M, Zhou J, Wang Z, Zhu X. Targeting E-cadherin expression with small molecules for digestive cancer treatment. Am J Transl Res 2019;7:3932–3944.
Metadaten
Titel
Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma
verfasst von
Feng-die Huang
Yan-ping Zhong
Guang-yu Sun
Qi-jiang Xu
Zhi-yong Xing
Ke-heng Chen
Lu-sheng Liao
Ming-you Dong
Publikationsdatum
28.01.2024
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08282-3

Weitere Artikel der Ausgabe 3/2024

Digestive Diseases and Sciences 3/2024 Zur Ausgabe

Original Article

A Novel Technique for the Management of Persistent Biliary Fistulas Developing After Liver Hydatid Cyst Surgeries: Drain Clamping Technique

Original Article

Hsa_circ_0014606 Derived from Exosomes Promotes Gastric Carcinoma Tumorigenesis and Proliferation by Sponging miR-514b-3p to Upregulate HNRNPC

Original Article

Predictors of Subsequent Celiac Disease Seropositivity in Patients Diagnosed with Duodenal Villus Atrophy on Upper Endoscopy

Original Article

Spatio-Temporal Feature Transformation Based Polyp Recognition for Automatic Detection: Higher Accuracy than Novice Endoscopists in Colorectal Polyp Detection and Diagnosis

Original Article

Planned Hybrid Endoscopic Submucosal Dissection as Alternative for Colorectal Neoplasms: A Propensity Score-Matched Study

Invited Commentary

Hypermobility, Trauma, and the Roads That Lead to Rome

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise